Drug intelligence / Profile preview

MCT-125

Development stage: Unknown
Lead developer: MultiCell Technologies
Modality: Small Molecules

Overview

**MCT-125** is an investigational small molecule drug developed for treating fatigue, the most common symptom in multiple sclerosis (MS). It works by increasing noradrenaline availability in the central nervous system, which reduces fatigue levels. Licensed from Amarin Corporation to MultiCell Technologies, it reached Phase IIb clinical trials managed by a clinical research organization.[1][3][5][9]

Beyond the preview

Go deeper on MCT-125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCT-125.

Explore the full profile